Search results
Biogen is a leading global biotechnology company that pioneers science and drives innovations for complex and devastating diseases. Biogen is advancing a pipeline of potential therapies across neurology, neuropsychiatry, specialized immunology and rare disease and remains acutely focused on its purpose of serving humanity through science while advancing a healthier, more sustainable and equitable world.
- Pipeline
With a strong focus on difficult-to-treat diseases, our...
- Responsibility
The CoLab, previously the Biogen Community Lab, is a...
- Alzheimer's Disease
Biogen’s commitment to health equity is rooted in efforts...
- Amyotrophic Lateral Sclerosis
Kate was busy planning her wedding when she was diagnosed...
- Lupus
Biogen’s decades of study at the crossroads of neurology and...
- Multiple Sclerosis
Over the past four decades, Biogen has been committed to...
- Spinal Muscular Atrophy
SMA, an inherited disease that can have a devastating effect...
- Pipeline
Biogen is a leading global biotechnology company that pioneers science and drives innovations for complex and devastating diseases. Biogen is advancing a pipeline of potential therapies across neurology, neuropsychiatry, specialized immunology and rare disease and remains acutely focused on its purpose of serving humanity through science while advancing a healthier, more sustainable and equitable world.
Biogen was founded in 1978 in Geneva as Biotechnology Geneva by several prominent biologists, including Kenneth Murray from the University of Edinburgh, Phillip Allen Sharp from the Massachusetts Institute of Technology, Walter Gilbert from Harvard University (Gilbert served as CEO during the start-up phase of Biogen), Heinz Schaller from the University of Heidelberg, and Charles Weissmann from the University of Zurich (Weissmann contributed the first product interferon alpha).
Jan 31, 2024 · Biogen will focus on LEQEMBI® (lecanemab-irmb) with Eisai and advancing potential new modalities to address the multiple pathologies of the disease and unmet patient needs. A plan for patients participating in clinical trials or on commercially available treatment is in place. Patients with questions are encouraged to call our patient support ...
Biogen is a global biotechnology company that develops innovative medicines for various diseases, including rare and neurological disorders. Follow its LinkedIn page to see its latest news, updates, events, and collaborations in the field of biotechnology research.
People also ask
How many followers does Biogen have?
Who is Biogen & why should you care?
Who is Biogen?
Is Biogen a stock?
May 22, 2024 · Biogen expects to finance the acquisition with cash and may also draw on its revolving credit agreement. The transaction is subject to customary closing conditions, including receipt of necessary regulatory approvals and is currently anticipated to close in the third quarter of 2024.
Sep 29, 2023 · About Biogen Founded in 1978, Biogen is a leading global biotechnology company that has pioneered multiple breakthrough innovations including a broad portfolio of medicines to treat multiple sclerosis, the first approved treatment for spinal muscular atrophy, and two co-developed treatments to address a defining pathology of Alzheimer’s disease.